CURAS fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Curasight A/S is a clinical development company. It engages in the business of exploiting a novel theragnostic platform with positron emissions tomography imaging and radionuclide therapy targeting the urokinase-type plasminogen activator receptor. The company was founded by Morten Persson, Andreas Kjær, Carsten Haagen Nielsen, and Jacob Madsen in 2013 and is headquartered in Copenhagen, Denmark.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
CURAS does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company